#lymsm Alert!
The largest dataset in #NLPHL with a whopping 2243 pts!

10 y PFS, OS, transformation rates 70.8%, 91.6%, 4.8%.

LP-IPS is here!
-age ≥45 y
-stage 3/4
-Hb <10.5
-Spleen+

Kudos to Michael Sargent Binkley, Jamie Flerlage and GLOW: Global nLPHL One Working Group team! Appreciate the collab. 🙏

International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma: important work by my Wilmot Cancer Institute colleague Jamie Flerlage Journal of Clinical Oncology
ascopubs.org/doi/full/10.12…

Very nice and usefull paper. Nodular Hodgkins deserve this! Big congrats to the GLOW team led by Michael Sargent Binkley! More to come! 🤝

👏 Nice work, kudos!

A huge congratulations to Drs. Michael Sargent Binkley & Jamie Flerlage and the entire GLOW: Global nLPHL One Working Group team on publication of an NLPHL-specific prognostic score (LP-IPS) in Journal of Clinical Oncology. Deeply grateful to have participated in this high-impact study! #lymsm #NLPHLsm ascopubs.org/doi/pdf/10.120…

Monumental effort by GLOW team in publishing the largest analysis of NLPHL to date and answering many key questions about age specific risks, the prognostic impact of variant patterns, and developing a new LP-IPS: ascopubs.org/doi/10.1200/JC… GLOW: Global nLPHL One Working Group Journal of Clinical Oncology Jamie Flerlage

Should NLPHL be reclassified with a grading criteria? Perhaps, but more evidence is needed, particularly for variant patterns. Our comment is posted (full affiliations to be added) Blood Journal GLOW: Global nLPHL One Working Group Jamie Flerlage Rachel Angelica Mariani Sharon M. Castellino
ashpublications.org/blood/article/…

GLOW: Global nLPHL One Working Group Humbled and deeply grateful for your support in highlighting our work on this captivating rare disease. United in our commitment, we will find the answer one day.

Very important abstract from #ASH23 by Dr. Marks et al. demonstrating that even low- and intermediate-risk NLPHL tumors are almost always PET-avid, enabling PET-based response assessment. #lymsm #NLPHLsm ashpublications.org/blood/article/… cc Kara Kelly Sharon M. Castellino

New abstract from #ASH23 by Ilja Kalashnikov 🇫🇮🇺🇦 et al. demonstrating that inferior outcomes in variant NLPHL may be associated with tumor microenvironment inflammation and checkpoint gene expression. #lymsm #NLPHLsm
ashpublications.org/blood/article/…

Excited to be opening this multicenter prospective study to study PROs in NLPHL! Thank you to Drs. Jamie Flerlage and Dr. Valerie Crabtree for your mentorship and the support of the entire GLOW: Global nLPHL One Working Group consortium. #lymsm

We at GLOW: Global nLPHL One Working Group got a shout-out at the 20th European Association for Haematopathology lymphoma workshop! Congratulations to our pathology committee as well as our co-founders Drs. Jamie Flerlage and Michael Sargent Binkley. #lymsm #NLPHLsm
ncbi.nlm.nih.gov/pmc/articles/P…

Our prospective observational study NLPHLPRO is now open at St. Jude Research! We are studying quality of life and patient-reported outcomes in patients with NLPHL.
Congratulations to PIs Drs. Ajay Major, MD, MBA, Dr. Valerie Crabtree, and Anna Jones. #NLPHLsm #lymsm
clinicaltrials.gov/study/NCT06098…

We're here in Memphis at the #ISCAYAHL meeting, led by our GLOW: Global nLPHL One Working Group founder Dr. Jamie Flerlage. Please say hello! #nlphlsm #ayacsm

Get pumped for ISCAYAHL 2023! I'm excited to be co-chairing the Health Outcomes session with Dr. Angela M. Feraco, MD MMSc. Looking forward to our invited speakers Drs. Parsons & AnnaLynn Williams, PhD as well as our oral abstract presenters. #lymsm #ayacsm stjude.org/education-trai…

Comment on the study by Eichenauer et al in ⁦Blood Journal⁩ on early stage NLPHL. NLPHL is an indolent B-cell lymphoma. How to treat? ⁦⁦⁦⁩What do you think?

NLPHL: a hummingbird in an owl’s nest | Blood | American Society of Hematology ashpublications.org/blood/article/…